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The prevalence of businesses selling autologous stem cell-based interventions to patients in Australia has
raised serious concerns about how weaknesses in regulation have enabled the emergence of an industry
that engages in aggressive marketing of unproven treatments to patients. Little is known about how pa-
tients experience this marketing and their subsequent interactions with practitioners. This paper reports
results from 15 semistructured interviews with patients and carers, and also draws upon discussion con-
ducted with patients, carers and family members (22 participants) in a workshop setting. We explore how
Australian patients and carers understand and experience these interventions, and how their presump-
tions about the ethics of medical practice, and the regulatory environment in Australia have conditioned
their preparedness to undergo unproven treatments.
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Background
Since the mid-2000s, scientists, medical professionals and regulators in Australia, Asia, Europe and North America
have been concerned about the provision and direct-to-consumer (DTC) marketing of stem cell-based inter-
ventions [1–3]. Initially, concerns focused on patients with serious medical conditions – multiple sclerosis (MS),
Parkinson’s disease, motor neuron disease (MND) spinal cord injury – traveling overseas to low-to-middle income
countries with weakly regulated medical infrastructure for procedures that lack demonstrated evidence of safety and
efficacy, and in some cases may not contain stem cells [4,5]. More recently, domestic markets for interventions that
use the patient’s own cells have become established in high income countries as well, including the USA, Japan,
Germany and Australia [4,6].
In Australia, the focus of this paper, approximately 70 privately owned clinics, mostly in metropolitan areas,
currently provide patients with unproven autologous stem cell-based interventions (ASCBI). ASCBI refers to
unproven procedures that use the patient’s own harvested cells, usually fat, blood or bone marrow, to treat a range
of conditions. Such interventions are offered primarily for the treatment of osteoarthritis (OA), but also for a wide
range of other purposes ranging from facial rejuvenation and hair restoration, to serious medical conditions such as
motor neurone disease, Parkinson’s disease, autism and dementia [7]. There is a lack of clarity about what is actually
administered to patients and none of the treatments are supported with high-level evidence. They carry uncommon
but significant risks, associated with extracting, preparing and administering the cells, and none are reimbursed by
public or private insurers. Patients pay significant sums out of pocket (AUD$6000 to more than AUD$30,000)
for interventions that are, at best, supported with only weak levels of evidence [8]. Moreover, the industry markets
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these interventions directly and aggressively to patients, in a manner that both exaggerates benefits and underplays
risks [7,9].
In this paper, we draw on data from interviews and two workshops with actual and prospective ASCBI patients
and their carers, to examine their understandings of and experiences with this industry. As we will show, patients’
assumptions and understandings often expose them to risk and direct harm, and make them vulnerable to the
direct marketing used by clinics.
Regulation & regulatory exemptions in Australia
Australia has a universal healthcare system characterized by values of patient care and equity, public health insurance
(Medicare), free access to public hospitals and the sequestering of medical practice from frank marketization. These
characteristics are articulated in the Health Insurance Act 1973, administrative laws governing public hospitals,
and, variously, the Therapeutic Goods Act 1989, the Health Practitioner Regulation National Law 2009 (the
National Law, 28), and the Australian Consumer Law, which sanction DTC advertising of medicines, set out the
professional responsibility of doctors and mandate compliance with codes of conduct which protect patients from
financial or other kinds of exploitation and from unsafe treatments.
Nevertheless, the stem cell industry was, until 2018, largely unfettered in Australia, primarily because regulators
based their light touch approach on an assumption that autologous cell treatments are low risk. Clinics have
been quick to develop business models which strategically exploited this approach. The Therapeutic Goods
Administration (TGA) has oversight of supply, import, export, manufacturing and advertising of therapeutics
including products derived from human cells and tissues. It takes a risk-based approach to regulation [10]. Since
2011, cellular material that is collected from a patient by a registered medical practitioner, manufactured and
administered back to the same patient by the same practitioner, or under their supervision, is not considered a
therapeutic good, and hence falls outside the TGA’s purview. This exemption for autologous biologicals has meant
that physicians have been able to freely offer ASCBI. It has also meant that unproven uses of autologous cells can
proceed without being tested in clinical trials or meeting stringent manufacturing standards.
TGA regulations have recently been revised, in response to the rapid growth in stem cell clinics and as evidence of
harm has emerged, including one death in Australia and a lengthening list of documented harms internationally [7,11].
After two rounds of public consultation, in 2015 and 2016 the TGA proposed a ban on DTC advertising of
autologous cell and tissue products [12]. It also proposed to regulate, under the Biologicals Regulatory Framework,
autologous cell and tissue products that are manufactured and used outside an accredited hospital, and that are
more than minimally manipulated and/or for nonhomologous use (nonhomologous use refers to cases where the
intended use requires the cells to perform a different basic function from their usual role in the tissue of origin).
This framework came fully into effect in July 2019, while the ban on advertising came into effect in mid-2018 [8].
The efficacy of the new legislation will depend on its enforcement, however. Other regulatory bodies like the
Australian Competition and Consumer Commission which regulates misleading advertising, or the Australian
Health Practitioner Regulation Agency which is concerned with practitioner conduct, have exercised little active
scrutiny of the sector.
Literature review
Although the literature commenting on these regulatory anomalies in Australia and internationally is now well
developed [4,7,9,13–22], there is little empirical evidence of the way patients themselves, and their carers, understand
and experience stem cell therapies and the expectations they have of their regulation. Almost all published fieldwork
that directly engages patient perspectives and experience is focused on the matter of international travel to obtain
SC interventions, and it is also concerned with a range of stem cell treatment types – embryonic, hematopoietic and
foetal – as well as autologous. If we examine this literature, we see that early qualitative studies of stem cell tourism
focus primarily on broad characterization of the patient groups and clinic destinations, often drawing on public
data like blogs and Twitter feeds [23,24]. Some more recent studies provide richly textured accounts of the reasoning
and experience of patients. Such studies report that patients are motivated by an absence of treatment options in
their own nations, by a sense of dwindling time available to identify a treatment or cure, and by qualified optimism
about their prospects in overseas clinics compared to what they sometimes regarded as deliberate obstruction from
their domestic clinicians [25,26].
Only one comprehensive study of Australian stem cell tourism has been carried out [27–29]. Based on interviews
with 24 patients and carers who had traveled overseas, and 46 clinicians and stem cell scientists and patients who
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had contemplated traveling abroad but elected not to pursue, the study found that patients traveled in order to
maintain hope in some degree of improvement for their condition. Patients are neither driven by wild optimism
nor by an absence of understandings of possible risks, but by the desire to have some agency in a situation where
they and their carers feel they cannot change the trajectory toward deterioration and disability, or indeed death,
if they remain within regulated national space. The desire for agency and a sense of autonomy, and to act as a
scientific pioneer is also highlighted in two studies that focus on Chinese destinations [30,31]. Each of these studies
identify a strong ‘right to try’ ethic among patients, a sense of both entitlement to access new treatments and a sense
of impatience with regulatory systems that prevented access. They felt an ethical imperative and ethical obligation
to take control of their own healthcare decision making, and could only do that by traveling to what they regarded
as innovative international clinics.
By contrast, there are no published, qualitative studies of patients who access their own domestic markets for
ASCBIs that we could identify at time of writing, despite the rapid escalation of such treatments in the USA, Canada
and Japan. Although there are important communalities between domestic and transnational patients accessing
unproven ASCBI, which we will explore below, there are some signal differences, particularly around attitudes to
biomedical and clinical regulation.
Methods
Data for this study were collected as part of the Australia Research Council funded project Regulating Autologous
Stem Cell Therapies in Australia’ from two workshops with patients, their carers and family members and interviews
with patients and their carers. The study was approved by the Human Research Ethics Committee of the University
of Sydney. Participants were recruited using an e-advertisement disseminated by grant partner organizations on
their websites, via newsletters and emails. For the workshops, participants nominated themselves in response to the
advertisement. For the interviews, the study recruited a purposive sample, that is, we selected participants based on
the characteristics of the population seeking ASCBIs, and the objectives of the study. We sought a range of disease
conditions, although some conditions, for example, MND were difficult to represent due to the seriousness of the
disease. We also sought a range of views about ASCBIs, from highly favorable to highly critical. Recruitment was
iterative, and the researchers actively discussed ways to balance a range of disease and ASCBI experiences.
Workshops were conducted in November 2016, one in Sydney and one in Melbourne. The workshops were
attended by 22 participants (9 men and 13 women). Out of these participants, 16 were patients with conditions
including OA and MS, one patient had an unspecified condition for which she needed a lung transplant, and another
had a balance disorder. Only one patient disclosed that he had undergone an ASCBI. Six participants were family
members accompanying the patients. Prior to the workshops, participants obtained a policy brief with a summary
of the legal and clinical aspects of ASCBIs in Australia to provide a basis for further discussion. The workshops were
designed to stimulate free debate and participants were not asked to come to an agreement or present any particular
positions regarding autologous stem cells. The workshops were chaired by a professional facilitator, participants
were asked about their views on autologous stem cells and patient access to these interventions. The workshops
were not audio recorded; Investigators took notes documenting major views presented by workshop participants.
Note that, in the absence of recorded data, we only draw on the workshop findings as background to the recorded
interview data.
Interviews were conducted in early 2017. Out of the 15 interview participants, 10 were women and five were
men, with an age range of 32–76 years. Fourteen participants were patients seeking treatment for themselves. Their
conditions included predominantly OA and MS. Other conditions included a tear in knee meniscus, an unspecified
spinal problem, and a balance disorder. Four had received ASCBI (three in Australia and one in the USA), one was
about to undergo an intervention (in Australia) and nine had considered having an ASCBI. One interviewee was a
carer for her husband who died of motor neurone disease shortly before the interview. Participants resided in the
cities of Sydney, Melbourne and Brisbane, and in rural Victoria. Demographic data was collected, including health
condition, gender, age and occupation. Three participants opted to not provide some elements of this information;
three omitted their age, and two only provided gender and health condition.
Out of the 15 interviews, four were follow-up interviews and 11 were interviews with participants who did not
attend a workshop. The interviews were semistructured, using a standardized questionnaire. All interviewees were
asked the same questions, in the same sequence. Semistructured interviews allow the interviewee to respond to
interview questions in an open-ended way and may lead to additional topics being covered. They are appropriate
for interviews that deal with complex topics and when the researchers seek in depth information [32]. The interview
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format was determined by the interview participant, in order to accommodate their health needs and personal
circumstances. They were given three different options (Skype, phone and face-to-face interview) and chose the
one most suitable to them and their needs. Twelve were conducted via phone, two via Skype and one face-to-face.
One interviewer conducted all the interviews. Participants were asked about their views on and experiences with
autologous ASC interventions, their understandings of regulation, presumed benefits and harms involved, and
ideal circumstances under which patients should have access to them. Interviews were recorded, transcribed and
coded in NViVo. The coder used grounded theory, the comparative approach [33,34]. Grounded theory is a well
validated, widely used method of inductive theory building that draws on in depth, qualitative data obtained
through purposive sampling, to identify the ways research participants understand their social world. Interviewees
are treated as co-constructors of the knowledge generated by research, and the interview is designed to elucidate
patterns of discursive reasoning and understanding in depth. The concerns they express and the patterns of
individual response across the different questions form the basis of analysis. Hence, the study coded data for the
primary themes emphasized and explored by the patients. Coding was verified by the research team.
Data analysis was hence thematic and conducted by the authors.
Results
The data suggest that patients’ consideration of and decision to undergo an ASCBI was shaped particularly by four
factors: illness experience, disillusion with current medical practice, unrealistic expectations of autologous stem
cells and trust in Australian healthcare regulation and clinicians. In what follows we trace this reasoning in detail.
Illness experience
Patients who took part in the study had conditions at different stages, with various levels of onset, severity and
prognosis. Most participants described their symptoms in terms of discomfort and deteriorated health and some
patients, particularly those with OA, spoke of experiencing pain. For example, a patient with OA described her
illness experience as follows.
“And I guess as I’m aging, and I have OA in my knees, and I fell over at work and fractured my ankle at the end of
last year, and now my ankle isn’t very good, even after doing physio, rehab, and . . . Pilates, which I still do. I don’t like
taking medication, besides which, it only just masks symptoms. It doesn’t actually improve the problem.” (Interview 8
patient OA, female, mid-fifties, clinical professional).
Another patient with OA said in a workshop that she lived on pain medication and expressed concerns about
the future development of her chronic condition. She stated that she would rather die than be immobile. For her,
the expected worsening of their illness and experiences with debilitating symptoms were the reasons for seeking
treatment with stem cells.
Finding cures was also an important issue for patients with MS. One explained that there were two ways of
looking at a cure. First, as stopping the disease and second, as recovering functionality that had been lost. This
patient had experienced a slowing in the progression of the illness but complained about the damage that MS has
done to him:
“It’s very annoying. I speak in this way, and I stop. Frequently. Just because things get stuck. And for me, that
was never – that was not the case. . . . people often said to me that I could talk under wet cement, and. . . yeah,
I could talk anywhere, and now I can’t. And I’m not great in certain situations, with lots of people around,
and I can’t plan very well anymore, and I can’t execute those plans, and all that sort of thing. It’s affected me
cognitively more than anything else, and that was kind of my bread and butter.” (Interview 9, patient, MS,
male, mid-fifties, professional).
For several patients, time played a significant factor in their illness experience. These were particularly patients at
a later stage of their condition or at an early stage of a condition with a serious prognosis. Several patients spoke
about ‘running out of time,’ to find a suitable therapy. One patient described the time concerns in the following
way:
“You don’t have much time. So I suppose it depends where you are along that spectrum, and how bad your
disease is, and how desperate you are to try new things, no matter how well they’ve been tested.” (Interview 3,
patient, MS, female, mid-sixties, retired professional).
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However, a few participants did not share this concern, due to the early stage of their condition or access to effective
medication. These patients saw their situation as fortunate. This included several patients with MS who felt that
they were ‘doing fine,’ especially because they had access to the medication they needed. Nevertheless, these patients
acknowledged the possibility that they might arrive at a difficult point at a later stage of their illness.
“I’m very well at the moment, I’m not looking for anything. I don’t need it, I’m traveling very well, but if I was
in a bad way, I’m damn sure I’d be out there, digging around to find out what other alternatives there might
be.” (Interview 3, patient, MS, female, mid-sixties, retired professional).
Some of these patients were keeping themselves updated on new developments with autologous stem cells, usually
through the newsletters of patient advocacy organizations such as MS Research Australia.
Dissatisfaction with standard medical practice
Patients were particularly interested in autologous stem cells due to their disillusionment with current standard
medical practice. The disillusionment had several aspects. First of all, some patients were concerned with the
absence of standard therapies available for their condition. This problem was discussed by patients and a carer in
the workshop with respect to MND, for which no standard medical therapy is currently available. Some participants
viewed autologous ASCBIs as their only option. Here we can see a similar desire for agency, a desire to do something,
evident in the experiences of patients who travel overseas described in the literature review.
Second, many patients wanted better therapies than those currently available to them in the Australian healthcare
system. A patient with arthritis described her view of knee replacement:
“From what I gather, they last about ten to fifteen years, so that would mean at my age I’d probably need to
have another one done, if I live over 65, and I’m very active, and I’d like to stay that way. And I don’t know,
it’s very strange if I had a part of my body in me that wasn’t actually me. So the possibility of not having to do
that is really appealing.” (Interview 11, patient, arthritis, female, early fifties, professional).
Patients especially desired less invasive solutions for their conditions than surgery. This was mentioned by several
patients with OA, who were concerned about the health implications of knee or hip replacement and wished to
avoid surgical interventions. One woman expected that she might need a lung transplant in the near future and
said that she would prefer stem cell therapy. In most cases, and despite the wide use of liposuction in ASCBIs,
patients assumed that having a transplant of their own stem cells would be less invasive than many standard medical
treatments, an assumption we discuss in detail below.
Another patient complained about the long waiting lists for knee or hip replacements. She explored treatments
for her knees and reported:
“I was told . . . that it was an 18 month to two years waiting list for knees. And you get people my age, getting
older, and have knee problems, and they can’t get any relief because – well, I’ve got a girlfriend who’s been
waiting for a least four or five years for a knee, because she has problems with her knee, and they keep telling her
she’s too young to have a knee replacement.” (Interview 13, patient, tear in the meniscus, female, mid sixties,
retired from a job in the education sector).
She reported that while she was consulting surgeons, she met a friend who had knee problems, yet was walking
properly. When she asked her which treatment she had, the friend told her about stem cell ‘therapy,’ which she
subsequently decided to try.
Overall, the absence of standard therapies, or a dislike or distrust of those available, was seen by many as a major
reason to explore novel clinical procedures. For example, a patient with MS who did not find autologous ASCBIs
exceptionally appealing noted:
“Well, they’re not necessarily more attractive, but at the moment, nothing else is really working, so I think
everything should be investigated.” (Interview 3, patient, MS, female, mid-sixties, retired professional).
Patients also raised the issue of desperation. This issue was most emphasized by patients suffering from pain, which
they perceived not only as a symptom of their condition but also as an effect of unsatisfactory standard medical
treatment. One patient in chronic pain, when asked if unproven interventions ought to be offered to patients, said:
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“No, I don’t think totally unproven. No. Not at all. Unless you’re totally desperate, and then I’d put my
hand up! (laughs). . . and I can imagine somebody . . . being treated with morphine year after year, if they
were promised something in Moscow, I could understand them going to Moscow! (laughs) I wouldn’t, but
I could understand somebody being totally desperate and trying anything.” (patient, back problem, male,
mid-seventies, self-employed).
Some patients expressed concerns that the lack of access to standard care, or unpalatable standard care, combined
with patients’ illness and desperation might place patients in a vulnerable position. Both interviewees and workshop
participants expressed concerns about these issues in the discussion.
We can see that these domestic patients share some of the drivers and concerns evident among patients who
sought overseas ASCBIs: both groups feel compelled by a sense of dwindling time, narrowing options, and a desire
for alternatives to what seems like an implacable, inflexible mainstream medical profession.
Autologous stem cells as safe & beneficial therapy
Participants’ interest in ASCBIs was shaped by a range of expectations about their perceived therapeutic effects.
Some participants envisaged that procedures using their own stem cells would have significant healing powers. An
interviewee argued that they were appealing because:
“...it’s coming from your own body. And the fact that it regenerates . . . It’s like wound healing. If you get the
right stuff, the wound actually builds itself up and you heal.” (Interview 8, patient, OA, female, mid-fifties,
clinical professional).
An MS patient described the interventions as magical, albeit with a degree of irony, as she admitted she had no
knowledge of how they worked.
“They seem to be able to rebuild or recreate something you’ve lost.” (Interview 3, patient, MS, female, sixties
retired professional).
Even the more wary patients, those that expressed concerns about ASCBIs and had not sought them out,
tended to equate autologous cells with safety, and the less sceptical equated them with a range of benign powers,
particularly the capacity to ‘naturally’ regenerate oneself. One patient interviewed, a medical professional who
had an autologous ASCBI for his knee OA and reported positive results, gave a very clear account of the line of
reasoning, equating autologous cells with a number of benign and productive qualities. Asked to compare ASCBI
with other interventions he stated:
“[The] other option for OA is a knee replacement, so that’s . . . you’re putting artificial materials into your
knee. It’ll never be the same. It’ll never have the same function. . . . so, autologous stem cell treatment is much
more attractive than that. It’s using your own body to regenerate itself. Putting stem cells from one area of your
body into another area, and stimulating regeneration. So, you know. It’s natural.” (interview 12, patient, OA,
male, early fifties, medical researcher).
Here, we can see that autologous cells are cast as less invasive, more natural, more effective and as self-regenerative,
all in the same breath.
Several patients contemplating hip or knee replacements made similar equations – autologous cells would be less
invasive, not ‘foreign,’ like prostheses, more natural:
“you’re using your own body’s cells . . . for me, that is quite compelling.” (Interview 4, patient, OA, female,
age and profession not supplied): “It’s very strange if I had a part of my body in me that wasn’t actually me.”
(Interview 11, patient, arthritis, female, early fifties, professional).
Some patients also framed the presumed easy nature of ASCBI in terms of time. Many of these patients envisioned
that the intervention involved a one-off treatment, a quick fix. A patient with OA who wanted to avoid a knee
replacement expected that stem cells would reduce convalescence:
“There’s no down time. You don’t have to spend time in hospital, you don’t have to have physiotherapy because
you’ve had a knee replacement. You just go in, you have the injection, then you get up and you walk out, and
you just get on with it.” (Interview 13, patient, tear in the meniscus, female, mid sixties, retired from a job
in the education sector).
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On the other hand, a patient doubtful about the promise of autologous ASCBI shared her concerns about the lack
of scientific evidence supporting their use:
“And I think it sounds so permanent, you know ‘stem cell’. Changing my stems! (laughs) Changing my cells!
What a great idea! I think theoretically it sounds fabulous, but I think that the attraction to this sort of therapy
would definitely be by people who are very unwell, and grasping at something that could potentially help them,
give them some sort of assistance, some sort of hope. Sometimes hope is just the greatest thing to have . . . but it’s
a pity that there’s nothing concrete out there.” (Interview 10, patient, MS, female, early sixties, hospitality).
Another MS patient goes on to note that one of the potential risks of ASCBI is psychological harm related to false
hope.
“[Patients are] putting their hopes on the line, and if it doesn’t work or it gets worse, yeah, people can get
depressed and it can affect their mental health.” (Interview 5, patient, MS, female, early forties, stay at home
mother).
Another concern raised by some participants related to financial harm, given the high cost of the interventions and
the lack of evidence supporting their use.
“Vulnerable people might be wasting money on things that have no scientific evidence whatsoever.” (Interview
1, patient, MS, female, early thirties, PhD student).
The general equation of ASCBI with safety, regeneration and beneficence derives from a number of sources. Patients
received most information about these interventions from popular media, patient advocacy groups and from other
patients, as well as the websites of the clinics themselves. Several patients mentioned that they have come across
media stories framing ASCBI as the latest scientific development and a new promising therapy. Some of these stories
involved celebrities who had received treatment and expressed satisfaction with their health results. In other words,
patients were strongly influenced by an ecology of marketing information that reinforced their impressions of the
innovative, safe and effective nature of ASCBI. We examine this ecology, and the ways that the TGA exemption
facilitates it, in the discussion section of the paper.
Trust in Australian Regulation & Healthcare
The majority of the patients had not considered the regulation of these interventions. At the time of the interviews,
most patients were unaware that they were neither regulated nor medically proven.
“I understand that if it’s being offered in Australia, it’s passed some type of regulation. But I couldn’t say anymore.
My expectation is that you can’t offer any medical service within Australia if there’s not a government body that’s
approved that procedure.” (Interview 14, patient, OA, male, mid-forties, manager).
More strikingly, this view was also shared by a patient who worked as a medical researcher at an Australian university.
She actively explored ASCBIs for her condition, and stated that:
“My presumption is that the types of treatments that go on in hospitals have gone through a certain TGA or
equivalent.” (interview 1, patient, MS, female, early thirties, PhD student).
When told that ASCBIs were excluded from regulation, she said:
“I sort of feel that if I’m presenting myself to a doctor, that all the treatments that they provide are going to
be regulated. So that would be my assumption, walking in the door. It surprises me that they’re not. . . . That
would seem to indicate to me that they [regulators] think there’s somewhat of a lesser risk involved.”
She was unconvinced that they were, in fact, lower risk, and had discontinued her pursuit of treatment.
It was clear in several of the interviews and in the workshop discussions that participants regarded good medical
regulation as a specifically Australian quality. As one patient put it:
“Well, I’m intrigued at why, in Australia, which has just got so many regulations, they’re not regulated.”
(interview 3, patient, MS, Female, mid-sixties, retired professional).
Another patient, who had undergone an ASCBI stated that:
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“I would never go overseas for a treatment: because I’d be really worried, and I wouldn’t trust any doctor from
overseas, or their regulations, but being in Australia, you think this will never, ever happen. You’d think this
would never be allowed.” (Interview 7, patient, balance disorder, male, mid-thirties, tradesman).
He had agreed to the procedure under the impression that he was receiving a well-regulated and proven form of
treatment.
It was evident that patients’ assessment of the risks for ASCBI was strongly influenced by the location of clinics in
Australia, rather than in a dubious international destination. They assumed that they would get a higher standard
of care than patients undergoing ASCBI abroad, particularly in developing countries. As one participant put it:
“if you go off to Russia to have that sort of stuff done, then you’re in totally unregulated territory because you’re
outside of Australia.” (interview 1, patient, MS, female, early thirties, PhD student).
A similar sense of safety, professional ethics and regulatory oversight was attributed to the Australian healthcare
system more generally, and to the doctors who provided the ASCBIs. Many participants not only expected that
interventions were regulated and approved, they also assumed that doctors were qualified to provide them and were
genuinely well meaning and concerned with their patients’ best interests.
“There would be certain regulations that . . . doctors can’t be cowboys and . . . that it’s all done properly. I
would like to know that whoever’s performing the stem cell therapy or treatment, that they are reputable people.”
(Interview 4, patient, OA, female, age and profession not supplied).
The extent of trust in the Australian healthcare system was illustrated by the many patients who, even after they
were informed that ASCBI were currently unregulated in Australia, continued to assumed that authorities, such as
the Medical Board of Australia, guarantee that clinicians do not provide untested or potentially unsafe procedures
to their patients:
“I’ve sort of – I suppose I trust our medical profession here, I trust our government to a reasonable degree. We’re
not a Third World country. . . We debate these things. I think we’re very lucky to live in this country, and so I’m
quite trusting of the safeguards that Australia puts in place.” (Interview 3, patient, MS, female, mid-sixties,
retired professional).
Some participants acknowledged the existence of ‘bad’ stem cell providers, for whom they used terms such as
‘cowboys’ or ‘charlatans.’ As one patient put it:
“[There are] unscrupulous physicians, I suppose, that are going to use autologous stem cell therapies for money-
making, for profit, and not putting the patient first, and possibly doing procedures that’s not their specialty, and
hence, not evidence-based. So, that’s the problem.” (interview 12, patient, OA, male, early fifties, medical
researcher).
He explained that these bad providers and ‘incidents’ that arose from the lack of TGA’s oversight gave stem cell
therapy a bad name. Nevertheless, he added, more stringent regulation would hinder research at a clinic with which
he is affiliated, both as a patient and researcher. With more regulation, he claimed, the research would be “nowhere
near . . . the stage that it’s at. It would be backward.”
Some participants implied that patients were responsible for identifying the ‘good providers.’ For example, one
interviewee said that patients should be ‘doing their own homework’ and ‘investigate reputable stem cell clinics.’ In
her view, “if you’re not prepared to do background checks, don’t bother” (Interview 4, patient, OA, female, no further
demographic data). She said that the state should regulate ‘pop-up clinics’ but it was a person’s choice whether
they wanted to go forward with a procedure. Her view was that stem cell research and interventions were exciting
innovations, and hence some degree of risk was to be expected.
Several patients also expressed views that suggested that they were inclined to trust stem cell providers over
doctors providing standard therapy. In particular, they held the view that general practitioners and specialists do
not want ASCBI to be promoted because they represent competition. As one patient clarified:
“[] stem cells dump them [orthopaedic surgeons] out of a job and out of money, because you don’t have to go
into hospital and stay there, and you don’t have to have a big operation on your knee or whatever it is, and you
just go in and have the injection and you get up and walk out.” (Interview 13, patient, tear in the meniscus,
female, mid sixties, retired from a job in the education sector).
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However, a few participants had serious concerns about the Australian healthcare system and its permissive approach
to ASCBI. These included a nurse who has searched for evidence supporting the interventions but did not find any
convincing data, and a participant who expressed a strong suspicion that clinicians look after their own interests
rather than those of their patients. One participant told of a particularly pernicious experience, one that had left
him with significant harm. The provider offered the patient a discount from AUD$12,000 to AUD$3000, while
emphasising that he was ‘doing him a favor.’ The clinic did not disclose comprehensive risk and efficacy information
to the patient during the consent-taking process and the patient agreed to the procedure under the impression that
it was regulated, clinically proven and safe. His account is striking because, first, it makes clear that he was not
afforded an opportunity for properly informed consent. Second, it encapsulates precisely the way clinics leverage
patients’ presumptions about the regulation of clinical practice and medical ethics in Australia.
“[The doctor] said, “Look, it fixes damage in your body. So if you’ve got damaged body parts, it will repair it.”
So I‘m thinking, well, no other doctor’s got help for me at the moment. I’ve been to see all the specialists, and
this bloke’s saying to me it’s a hundred percent safe. Now, had he told me it wasn’t a hundred percent safe and it
was experimental, there’s no way in the world I would have done it, because I’m quite a cautious guy, so I’m not
going to go – that’s why I consulted with him twice; because I was still in doubt that it was safe, but because he
kept saying it was safe, and he is a doctor, I just believed him. You know what I mean? And especially being in
Australia, I believed what he was saying to me.” (Interview 7, patient, balance disorder, male, mid-thirties,
tradesman).
Several other patients noted that they did not receive any information about possible risks. They had simply been
told that it should work. The majority of study participants held the view that patients need to be given full
and transparent information about ASCBI, including whether they are proven or not. On being made aware of
the unproven nature of treatments, several participants expressed concerns about the exploitative nature of such
for-profit clinics. One patient noted the opportunity for providers to ramp up the number of interventions, each
of which incurs a charge:
“It’s suggested that each treatment will do the trick, but when people come into it more, it’s then suggested to
them that they might need four or five treatments, and each treatment seems to be in the region of $20,000.”
(Interview 2, patient, OA, female, age not provided, clinical professional).
When the issue of providers’ conflict of interest was raised and discussed in workshops, many participants empha-
sized the need to protect vulnerable people, particularly because they invested trust in medical professionals. An
interviewee stated succinctly:
“It [should] come under the umbrella of any and every procedure, and not be pulled out” and said, “Well,
it’s your cells, therefore it’s your problem.” (Interview 2, patient, OA, female, age not provided, clinical
professional).
As participants assumed that autologous ASCBI were regulated, most of them also assumed that they were a proven
therapy. As one patient who has undergone an [unproven] ASCBI in the USA put it:
“I felt reassured that there was a basis for it, there was a sound medical basis for it.” (Interview 15, patient,
back problem, male, mid-seventies, self-employed).
Only a handful of participants were aware of the absence of medical evidence for the safety and efficacy of
autologous ASCBI for their particular conditions.
Discussion
We can see in the interviewees’ accounts that they rely on a set of presumptions about the regulatory environment
and protections, which they assume are intrinsic to the Australian healthcare system and health product market.
They trusted in the efficacy and proven status of ASCBI, and as patients, they assumed they were protected from
opportunistic medicine by a rigorous and uniformly applied national regulatory armature. The clinics’ capacity to
recruit patients prepared to undergo unproven treatments depended directly on these presumptions.
This trust led many patients to put possible concerns aside, and to consider or enter into interventions that
several note they would never contemplate if they were offered in another country. Patients formed the intention
to seek treatment in Australian stem cell clinics precisely because they were not overseas. Traveling to Russia or
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China or the Cayman Islands was regarded as dangerous, exploitative, and a destination for the desperate and
vulnerable. ASCBI at home, on the other hand, were attributed with a high degree of safety, and the providers were
attributed with expertise and empathy. These assumptions prevailed despite the fact that patients often described
an opportunistic and poorly qualified element among clinical providers, who were prepared to neglect broader
principles of informed consent in order to secure a paying customer. Under Australian law [35], and codified by
the National Law and the Australian Medical Board guidelines [36], health practitioners have a duty of care to the
patient to provide them with information about the material risks of having and not having an intervention, and to
compare it with other available treatments. However, the patients’ accounts suggest that Australian providers fail to
observe this duty in most cases, and instead clinicians made unfounded claims about the safety and efficacy of the
interventions. So, we can see that the stem cell industry leveraged the trust Australians have in health regulation,
while at the same time operating in a space undisturbed by effective regulation.
The use of DTC websites meant that clinics could purvey their interventions as safe, proven, benign and natural,
without the need for peer-reviewed research, clinical trials or any other mandated standard of clinical evidence. In
our analysis of websites marketing ASCBI [37], we found that clinics were adept at using what Sipp et al. (2017) have
termed ‘tokens of legitimacy’ [9]. These tokens give a veneer of scientific credibility to unsupported claims about
the risks and benefits of ASCBI, including registrations of phantom clinical trials on unmoderated registration
websites, membership of professional associations that are in fact industry advocates, and reference to unrecognized
forms of medical expertise, for example, ‘stem cell specialists.’
The power of such marketing is evident in the wide acceptance, among even the more critical study participants,
of the qualifications of providers and of the ground-breaking nature of the interventions on offer. Prior to extended
discussion in the workshops and interviews, participants were largely persuaded that ASCBI were more efficacious
than other available treatments, or at minimum, would be worth considering as an alternative. The autologous
nature of the interventions was pivotal here. In their accounts, patients considered autologous procedures as
intrinsically safe. The cells’ status as ‘self ’ tissue was associated with a natural and minimally invasive treatment,
and with easy recovery. Autologous tissue delivered by injection was favorably contrasted with donor tissues and
medical devices, with risks of immune suppression and waiting lists, and with surgery: invasive, risky and involving
long recover times.
More broadly, the portrayal of ASCBI on clinic websites and in other areas of mass and social media builds on
popular associations of stem cells with self-regeneration and the miraculous reversal of ill-health [38]. The clinics
could benefit from a broader ecology of information and popular understanding that predisposed patients and
carers toward an optimistic view of ASCBI. In contrast, the study results suggest that expert information about the
unregulated and unproven nature of these interventions was not easily available, even to well-educated professionals.
Limitations of the study
Our study findings are based on a small sample. While small numbers of in-depth interviews are appropriate for
qualitative methods, this nevertheless may limit the degree of generalizability of the findings. The poor health of
patients seeking ASCBI also limited the range of medical conditions experienced by our sample. The use of different
technologies for interview (Skype, telephone, face to face) may have influenced interactions between interviewer
and interviewee.
Conclusion
The TGA exemption of autologous cells and tissues from regulatory oversight opened up the way for opportunistic
providers to colonize the public domain with unfounded claims and develop a lucrative market of paying patients.
It is evident that health consumers need better access to reliable information about the relative risks and benefits
of autologous ASCBIs. Currently, they have only access to passive information that is available on the websites
of publicly funded institutions, such as Stem Cells Australia, and patient advocacy groups. To promote more
informed decision making, dedicated funding is needed for support centers that patients can contact and receive
information in a timely and responsive manner. Furthermore, ongoing review of the new TGA regulations is needed
to ensure they actually address the conflicts of interest evident in the sector, and guard against the exploitation
of new loopholes, such as the ‘hospital use’ exception to continue operating business as usual. Review is also
needed for the process that are meant to protect consumers from exploitation; namely, the lodging and following
of complaints made to the Australian Competition and Consumer Commission, the Medical Board of Australia
and other professional governance agencies.
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Executive summary
• This study investigates the knowledge, understanding and experience of patients and prospective patients as
they interact with the direct-to-consumer market for unproven stem cell-based interventions in Australia.
• It provides an account of the development of a poorly regulated autologous stem cell-based interventions
(ASCBI) sector in Australia, and of recent attempts to improve regulation.
• The study is based primarily on interviews with 15 patients and carers, and also draws upon discussion conducted
with patients, carers and family members (22 participants) in a workshop setting.
• The interviews identified four factors that led patients to consider or undertake an ASCBI: illness experience,
disillusion with current medical practice, unrealistic expectations of autologous stem cells, and trust in Australian
healthcare regulation and clinicians.
• The study finds that patients were not aware that ASCBIs were unproven treatments.
• It finds that patients reported a high degree of trust in the Australian regulatory environment, and assumed that
the ASCBI clinics were properly regulated.
• It concludes that patients need better access to reliable information about the relative risks and benefits of
autologous ASCBIs and ongoing review of the new Therapeutic Goods Administration regulations is needed to
ensure they address the conflicts of interest evident in the sector.
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